信使核糖核酸
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
病毒学
生物
2019年冠状病毒病(COVID-19)
分子生物学
医学
基因
遗传学
病理
疾病
传染病(医学专业)
作者
Byron Brook,Valérie Duval,Soumik Barman,Lauren Speciner,Cali Sweitzer,Asad Khanmohammed,Manisha Menon,K. Wade Foster,Pallab Ghosh,Kimia Abedi,Jacob Koster,Etsuro Nanishi,Lindsey R. Baden,Ofer Levy,Thomas C. VanCott,Romain Micol,David J. Dowling
出处
期刊:Science Translational Medicine
[American Association for the Advancement of Science (AAAS)]
日期:2024-07-24
卷期号:16 (757)
被引量:1
标识
DOI:10.1126/scitranslmed.adm8451
摘要
Messenger RNA (mRNA) vaccines were pivotal in reducing severe acute respiratory syndrome 2 (SARS-CoV-2) infection burden, yet they have not demonstrated robust durability, especially in older adults. Here, we describe a molecular adjuvant comprising a lipid nanoparticle (LNP)-encapsulated mRNA encoding interleukin-12p70 (IL-12p70). The bioactive adjuvant was engineered with a multiorgan protection (MOP) sequence to restrict transcript expression to the intramuscular injection site. Admixing
科研通智能强力驱动
Strongly Powered by AbleSci AI